Syros Pharmaceuticals Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Syros Pharmaceuticals's estimated revenue is currently $2.1M per year.
- Syros Pharmaceuticals received $40.0M in venture funding in February 2018.
- Syros Pharmaceuticals's estimated revenue per employee is $20297
- Syros Pharmaceuticals's total funding is $165.8M.
- Syros Pharmaceuticals has 101 Employees.
- Syros Pharmaceuticals grew their employee count by 11% last year.
- Syros Pharmaceuticals currently has 1 job openings.
|Eric Olson||Chief Scientific Officer|
|Matthew Eaton||Associate Director, Computational Biology|
|Charlie Pak||VP of New Product Planning|
|Hina Jolin||Associate Director|
|Anneli Savinainen||Director Preclinical Pharmacology and Toxicology|
|Keisha Thomas||Associate Director, Corporate Development|
|Graeme Hodgson||Senior Director Translational Medicine|
|Sara Mathews||Associate Director, Clinical Science|
|John Carulli||Vice President, Biology|
|Tiffany Crowell||Vice President, Clinical Operations|
What Is Syros Pharmaceuticals?
Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros lead drug candidates are SY-1425, a selective RAR agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$7.8M||42||50%|
|Long Term Pharm...||$10.3M||55||10%|
Syros Pharmaceuticals News
The new facility will give the Cambridge-based biotech capacity to double its 80-person employee base. Subscribe to get the full story.
Founded in 2012, Syros Pharmaceuticals is a pioneering life sciences company focused on a new area of medicine called gene therapy.
Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a ...
Syros Pharmaceuticals Funding
|2013-04-12||$30.0M||A||ARCH Venture Partners, Flagship Ventures||Article|
|2016-01-13||$40.0M||Undisclosed||Deerfield Management Company||Article|
|2018-02-01||$40.0M||Undisclosed||JMP Securities LLC||Article|
Syros Pharmaceuticals Executive Hires
|2013-05-23||Eric R. Olson||Chief Scientific Officer||Article|
|2014-06-11||Jorge Conde||CFO/Chief Product Officer||Article|
|2015-05-01||Jonathan Garen||Chief Business Officer||Article|
|2015-12-08||David A. Roth||Chief Medical Officer||Article|
|2016-09-27||Gerald E Quirk||Chief Legal Officer||Article|
|2017-11-14||Jeremy Springhorn||Chief Business Officer.||Article|